Evaluation of ROTARIX(®) Booster Dose Vaccination at 9 Months for Safety and Enhanced Anti-Rotavirus Immunity in Zambian Children: A Randomised Controlled Trial

Oral rotavirus vaccines show diminished immunogenicity in low-resource settings where rotavirus burden is highest. This study assessed the safety and immune boosting effect of a third dose of oral ROTARIX(®) (GlaxoSmithKline) vaccine administered at 9 months of age. A total of 214 infants aged 6 to...

Descripción completa

Detalles Bibliográficos
Autores principales: Laban, Natasha Makabilo, Bosomprah, Samuel, Simuyandi, Michelo, Chibuye, Mwelwa, Chauwa, Adriace, Chirwa-Chobe, Masuzyo, Sukwa, Nsofwa, Chipeta, Chikumbutso, Velu, Rachel, Njekwa, Katanekwa, Mubanga, Cynthia, Mwape, Innocent, Goodier, Martin Rhys, Chilengi, Roma
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9960729/
https://www.ncbi.nlm.nih.gov/pubmed/36851224
http://dx.doi.org/10.3390/vaccines11020346

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9960729/
https://www.ncbi.nlm.nih.gov/pubmed/36851224
http://dx.doi.org/10.3390/vaccines11020346

Ejemplares similares